Finland· FI-REL-REL39831

Telzir

A fosamprenavir product containing fosamprenavir calcium, registered in Finland by Paranova Oy. The same ATC class is registered in 8 of our 19 countries.

ATC J05AE07

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedTelzirATCJ05AE07REGISTER NO.FI-REL-REL39831PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Fosamprenavir is registered in 8 of 19 countries.

Countries holding a registration under ATC J05AE07 (fosamprenavir), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 6 of them publish a price we can compare per daily dose

Fosamprenavir · ATC J05AE07

8 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fosamprenavir costs, country by country.

Normalised to the WHO defined daily dose (1.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Fosamprenavir · price per daily dose (1.4 g)

USD · FX 28 Sept 2026

  • FR France$13.86
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Fosamprenavir calcium
Manufacturer
Paranova Oy
Country
Finland (FI)
ATC code
J05AE07
ATC class
Fosamprenavir
Defined daily dose
1.4 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

336 interactions on record for fosamprenavir.

Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fosamprenavir · interactions on record

336 records

  • 116 severe
  • 186 moderate
  • 7 minor
  • 25 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • LoperamideA07DA03severe
  • BudesonideA07EA06severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a8f9ec07-5fae-47a2-b3f3-e52d47144008
GET /v1/drugs/a8f9ec07-5fae-47a2-b3f3-e52d47144008?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "1.4",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "700 mg",
  "atc_label": "fosamprenaviiri",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/04/282/001",
  "fimea_rel_id": "REL39831",
  "authorised_at": "2011-04-04"
}

See everything about fosamprenavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.